Sareum now has excellent prospects for funding their pipeline of preclinical molecules following their recent deal. As the market for kinase inhibitors gets ever hotter expect this company to be the focus of further industry attention.
Money at last for Sareum. All good things to those that wait. Kinase inhibitors are big money nowadays with commercial versions adding as much as $5 billion to an acquisition deal e.g., Onyx. Sareum has a great development tie up with SRI international as well so expect some fireworks ahead share-price-wise. r Strong BUY